Biologic Therapies Summit

Healio Rheumatology features the top stories from the Interdisciplinary Autoimmune Summit. More of Healio Rheumatology’s live coverage, including video interviews with researchers, can be found by clicking here.

CLEVELAND — At the Biologic Therapies VII Summit, Leonard Calabrese, DO, professor of medicine at the Cleveland Clinic and Chief Medical Editor of Healio Rheumatology, described how to prevent serious infections in patients with immune-mediated inflammatory diseases.

CLEVELAND — At the Biologic Therapies VII Summit, Kevin L. Winthrop, MD, MPH, associate professor at Oregon Health & Science University, reviewed the best vaccine practices for patients with immune-mediated inflammatory diseases.

CLEVELAND — Christopher Ritchlin, MD, MPH, professor of medicine at the University of Rochester Medical Center, reviewed treatments for psoriatic arthritis, spondyloarthritis and other spondyloarthropathies at the Primary Vasculitides Pre-symposium of the Biologic Therapies VII Summit.

CLEVELAND — At the Biologic Therapies VII Summit, Jonathan Kay, MD, professor of medicine at the University of Massachusetts Medical School, reviewed the role of biomarkers in predicting outcomes for patients with rheumatoid arthritis.

CLEVELAND — At the Biologic Therapies VII Summit, Edward Keystone, MD, FRCP(C), professor of medicine at the University of Toronto, discussed the potential window of opportunity in the management of rheumatoid arthritis based on disease duration.

CLEVELAND — Conventional therapy still has a role in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis; however, there are many factors that need to be examined for each patient, according to Carol A. Langford, MD, MHS, director for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases at the Cleveland Clinic, said in her presentation at the Primary Vasculitides Pre-symposium of the Biologic Therapies VII Summit.

CLEVELAND — Leonard H. Calabrese, DO, of the Cleveland Clinic and Chief Medical Editor of Healio Rheumatology, provided a diagnostic update for patients with central nervous system vasculitis at the Primary Vasculitides Pre-symposium of the Biologic Therapies VII Summit.

CLEVELAND — At the Biologics Therapies VII Summit, Michael E. Wechsler, MD, MMSc, professor of medicine and director of the Asthma Institute at National Jewish Health in Denver, spoke about eosinophilic granulomatosis with polyangiitis and the role of biologics, which include mepolizumab and reslizumab.

CLEVELAND — At the Biologics Therapies VII Summit, Peter A. Merkel, MD, MPH, professor of medicine and epidemiology and chief of rheumatology at the University of Pennsylvania, spoke about biologics for the treatment of giant cell arthritis, which include abatacept and tocilizumab.